| Male n (%) |
24 (65) |
| Age, yr (median, yr) |
73.9±14.9 (78) |
| Clinical diagnosis |
|
| Pulmonary TB |
26 |
| Miliary |
5 |
| Pulmonary and pleural |
4 |
| Pleural TB |
2 |
| Initial treatment with Z n (%) |
23 (62) |
| Main adverse effect |
|
| Liver dysfunction |
14 |
| Eruption |
9 |
| Fever |
8 |
| Others |
6 |
| Total deaths |
7 |
| Cause of death |
|
| Congestive heart failure |
5 |
| Renal failure |
1 |
| Cerebral infarction |
1 |
| LST (positive:negative) |
10:14 |
| Treatment completion n (%) |
30 (81) |
| Final treatment |
|
| HRE |
25 |
| HREZ |
2 |
| Others |
3 |
TB: tuberculosis, LST: lymphocyte stimulation test, H: isoniazid
R: rifampicin, E: ethambutol, Z: pyrazinamide |
